key: cord-0765592-0b6awuws
authors: Arora, Prerna; Kempf, Amy; Nehlmeier, Inga; Graichen, Luise; Sidarovich, Anzhalika; Winkler, Martin S.; Schulz, Sebastian; Jäck, Hans-Martin; Stankov, Metodi V.; Behrens, Georg M. N.; Pöhlmann, Stefan; Hoffmann, Markus
title: Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
date: 2021-10-11
journal: Cell Mol Immunol
DOI: 10.1038/s41423-021-00772-y
sha: b8ece1a2399fc38f4808d2c142d43b945f45e007
doc_id: 765592
cord_uid: 0b6awuws

nan

monoclonal antibodies and sera/plasma from infected or BNT162b2/Comirnaty vaccinated individuals [8, 9] . The Delta Plus and Delta-V variants entered the Vero and 293T kidney-derived cell lines with similar efficiency as the Delta variant and WT virus (Wuhan/Hu-1/2019 isolate with the D614G mutation) (Fig. 1C) . Furthermore, entry of the Delta variant into the lung-and colonderived cell lines Calu-3 and Caco-2 was enhanced, in keeping with a previous study [8] ; an increase in entry efficiency was also observed for the Delta Plus and Delta-V variants (Fig. 1C) . The Delta variant was resistant to neutralization by the monoclonal antibody bamlanivimab, whereas Delta Plus was resistant to both bamlanivimab and etesevimab (Fig. 1D) , with resistance to the latter most likely due to the K417N mutation [10] . Finally, the Delta variant showed reduced neutralization by antibodies induced by SARS-CoV-2 infection and BNT162b2/Comirnaty vaccination, in agreement with previous findings and in line with data for its parental lineage B.1.617 [2-4, 8, 9, 11] and neutralization of the Delta Plus and Delta-V variants was reduced to similar levels ( Fig. 1E , F).

Our results reveal no appreciable differences between host cell entry and neutralization sensitivity of the Delta variant and its sublineages, with the notable exception of the Delta Plus variant being resistant to both bamlanivimab and etesevimab, which are used in cocktails for COVID-19 treatment. Although T-cell responses were not analyzed in the present study and confirmation of the data using authentic virus and primary cells is pending, our results suggest that neither the Delta Plus nor the Delta-V variant is associated with an increased threat to convalescent or BNT162b2/Comirnaty vaccinated patients compared to the founder virus. Finally, it is noteworthy that heterologous ChAdOx1 nCov-19/BNT162b2 vaccination might provide particularly robust protection against these viruses [12] . Transduction efficiency was quantified as described above. For normalization, WT S protein-driven entry in the absence of monoclonal antibody was set as 0% inhibition. The average of four technical replicates is shown. Error bars indicate the standard deviation (SD). E, F Particles bearing the indicated S proteins were incubated for 30 min at 37°C in the presence of different dilutions of convalescent plasma (E) or vaccinee serum (F) before being inoculated onto Vero cells. Transduction efficiency was quantified as stated above and used to calculate the plasma/serum dilution factor that leads to a 50% reduction in transduction (neutralizing titer 50, NT50). Data for nine convalescent plasma samples and fourteen vaccination serum samples are presented. Black lines indicate the median, and numbers in brackets represent the fold change in NT50 compared to WT SARS-CoV-2 S (dashed line = detection limit). Statistical significance was analyzed by two-tailed Student's t test ( ns p > 0.05; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 16

Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2

Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination

SP and MH conceived of the project. PA and MH designed the experiments. SP wrote the paper; all authors revised the paper. PA, AK, IN, LG, AS, and MH performed the experiments. MSW, SS, HMJ, MS, and GB provided essential reagents.

Open Access funding enabled and organized by Projekt DEAL.

The authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41423-021-00772-y.Correspondence and requests for materials should be addressed to Stefan Pöhlmann or Markus Hoffmann.Reprints and permission information is available at http://www.nature.com/ reprintsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.